Teva and Celebrex maker Pfizer (PFE) reached a settlement on April 17 regarding Teva's generic version which it plans to launch in December of this year. According to IMS, the branded product generated $2.2B in U.S. sales in 2013.
Jeffries says that it is unlikely that generic Copaxone will be introduced this quarter. The European Patent Court affirmed Teva's Copaxone patent until 2025. Why then did Teva lose almost a Dollar today?
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that the European Patent Office issued a decision in favor of Teva in a patent opposition proceeding filed by Synthon BV, Mylan and an unidentified third party. On September 6, 2012, the three opponents commenced an opposition proceeding against European Patent EP 2 177 528, a patent for COPAXONE® (glatiramer acetate injection) expiring September 9, 2025. In today's hearing, the European Patent Office specifically determined that claims 1-12 of the '528 patent are valid. Therefore infringing follow-on glatiramer products would not be able to launch prior to patent expiry.
Spam = virus infested phishing scam = garbage = virus infested phishing scam = garbage = avoid
spam +++ pam +++ spam +++ spam +++ spam +++ spam +++ spam +++ spam +++ spam +++ spam
wow, i just can't believed it how this site really change my life'....you guys have checked it out! thank you so much for the recommendation OP